Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and Carcinoma, Neuroendocrine

erlotinib hydrochloride has been researched along with Carcinoma, Neuroendocrine in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gu, FF; Hong, XH; Liang, JY; Liu, L; Liu, YY; Tong, F; Zeng, YL; Zhang, K1
Baglivo, S; Chiari, R; Crinò, L; Ludovini, V; Messina, S; Metro, G; Rebonato, A; Ricciuti, B; Sidoni, A; Siggillino, A1
Byeon, JH; Jung, YH; Kim, HR; Kim, TJ; Lim, JU; Park, CK; Woo, IS1
Costa, DB; Desai, NV; Folch, E; Gangadharan, SP; Huberman, MS; Karp, RS; Kent, MS; Le, X; Majid, A; Rangachari, D; VanderLaan, PA1
Anthoney, A; Blatter, J; Dean, E; Hanauske, AR; Kletzl, H; Klingelschmitt, G; Melezinek, I; Ranson, M; Reck, M; Twelves, C1
Bago-Horvath, Z; Berger, W; Filipits, M; Grusch, M; Haitel, A; Hayden, H; Komina, O; Lackner, A; Pirker, C; Schmid, K; Sieghart, W; Węsierska-Gądek, J1
Kimura, Y; Morikawa, N; Murakami, K; Nagano, Y; Tabata, T; Yanagisawa, S1
Gonzalez, D; Nicholson, AG; Nutting, CM; O'Brien, M; Popat, S; Wotherspoon, A1

Trials

1 trial(s) available for erlotinib hydrochloride and Carcinoma, Neuroendocrine

ArticleYear
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Time Factors; Tissue Distribution; Treatment Outcome

2010

Other Studies

7 other study(ies) available for erlotinib hydrochloride and Carcinoma, Neuroendocrine

ArticleYear
Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.
    Medicine, 2017, Volume: 96, Issue:21

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel

2017
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer.
    Mayo Clinic proceedings, 2017, Volume: 92, Issue:8

    Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors

2017
Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.
    The Korean journal of internal medicine, 2014, Volume: 29, Issue:6

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome

2014
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.
    Lung cancer (Amsterdam, Netherlands), 2015, Volume: 88, Issue:1

    Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Neuroendocrine; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Fatal Outcome; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Radiography; Small Cell Lung Carcinoma

2015
Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
    Neuroendocrinology, 2012, Volume: 96, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Child; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Young Adult

2012
Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.
    Respirology (Carlton, Vic.), 2012, Volume: 17, Issue:8

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Treatment Failure; Vinblastine; Vinorelbine

2012
Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.
    Lung cancer (Amsterdam, Netherlands), 2013, Volume: 80, Issue:1

    Topics: Adenocarcinoma; Carcinoma, Neuroendocrine; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Grading; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma

2013